Validation of Viral Inactivation/ Elimination Protocols for Therapeutic Blood Products (TBP) against Emerging and Re-emerging Viruses: Specific Cases of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2) and Ebolaviruses (EBOV)

Taipei Medical University Institutional Repository > 醫學工程學院 > 國際生醫工程博士學位學程 > 博士論文 > Item 987654321/63185

請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/63185

題名:	Validation of Viral Inactivation/ Elimination Protocols for Therapeutic Blood Products (TBP) against Emerging and Re-emerging Viruses: Specific Cases of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2) and Ebolaviruses (EBOV)
作者:	BELEM, WENDIMI FATIMATA
貢獻者:	��ڥ��u�{�դh�Ǧ�ǵ{ BURNOUF, THIERRY LIN, LIANG-TZUNG
關鍵詞:	SARS-CoV-2;Ebolavirus;COVID-19/Ebolavirus disease convalescent plasma/serum;neutralizing antibodies;Pathogen reduction technology
日期:	2023-06-15
上傳時間:	2023-12-07 09:54:01 (UTC+8)
摘要:	Introduction Convalescent plasma (CP) or concentrated immunoglobulin (Ig) preparations have been used in the COVID-19 pandemic and the different Ebolavirus (EBOV) disease (EVD) outbreaks as a possible prophylactic or therapeutic option. However, blood product therapy presents pathogen safety issues that need to be addressed to support the safety of the therapy. Several pathogen reduction technologies including solvent/detergent (S/D) treatments have been engineered and applied to plasma for transfusion to provide a significant assurance of viral safety. Additionally, several viral inactivation/removal methods including nanofiltration, have been engineered and implemented in the production process of Igs. Aims The goal of this Ph.D. research work is to evaluate: (1) the impact of S/D [S: 1% Tri-n-butyl phosphate (TnBP) and D: 1% TritonX-100 or 1% TritonX-45)] treatments of plasma on SARS-CoV-2 infectivity and on the functional neutralizing activity of SARS-CoV-2 Abs in COVID-19 convalescent plasma and (2) the impact of Planova 35N nanofilters on the removal of EBOV infectivity and ability of Abs to neutralize EBOV in human Ig solutions. Materials and methods The SARS-CoV-2 pseudovirus (SARS-CoV-2pp) and EBOV-like particles (EBOV VLP) were produced by transfection of HEK293FT cells. The S/D treatments of plasma were done at 31�XC for 30 min followed by filtration through a Sep-Pak Plus C18 cartridge. The human IgG solution was subjected to nanofiltration according to the manufacturer's recommendation. The virus inactivation and neutralizing assay were performed by infecting Huh-7 cells. Results We successfully produced SARS-CoV-2pp and EBOV VLP as surrogate models of native viruses. The absence of toxicity in different samples was demonstrated before the infectivity assay. Complete inactivation of SARS-CoV-2pp (over 4Log10) and complete removal of EBOV VLP (over 3Log10) without the detection of residual virus in the products as well as the preservation of the neutralizing activity of Abs in COVID-19 convalescent serum and EVD plasma-derived polyvalent immunoglobulin models were observed after completion of both S/D treatments and Planova 35N filtration. Conclusion The major treatments and nanofiltration have been engineered to inactivate or remove viruses from CP or IgG solution and appear effective at reducing SARS-CoV-2 and EBOV without altering the neutralizing activity of their Ab content
描述:	�դh ��ɱб�:BURNOUF, THIERRY �@�P��ɱб�: LIN, LIANG-TZUNG �e��:CHUANG, ER-YUAN �e��:COGNASSE, FABRICE �e��:LIN, JING-YI �e��:BURNOUF, THIERRY �e��:LIN, LIANG-TZUNG
資料類型:	thesis
顯示於類別:	[國際生醫工程博士學位學程] 博士論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	72	檢視/開啟

在TMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....